Erasca Inc
Veridion Score
Composite trend over time
Why is ERAS moving today?
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for ERAS.
ERAS insider activity
Erasca Inc
No multi-insider buying cluster in the last 90 days
Net selling: -$1.9M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-03 | 2026-04-01 | Garner Ebun | Insider | sell | $16.40 | 80,000 | 25,076 | $1.3M | SEC Form 4 |
| 2026-04-03 | 2026-04-01 | Garner Ebun | Insider | buy | $1.70 | 80,000 | 105,076 | $136K | SEC Form 4 |
| 2026-03-06 | 2026-03-04 | Morris Shannon | Insider | sell | $15.04 | 20,000 | Not reported | $301K | SEC Form 4 |
| 2026-03-06 | 2026-03-04 | Morris Shannon | Insider | buy | $1.70 | 20,000 | 20,000 | $34K | SEC Form 4 |
| 2026-01-30 | 2025-12-15 | Chacko David M. | Insider | buy | $1.19 | 17,793 | 279,980 | $21K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 3 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moERAS contract awards, year to date.
Public federal awards linked to this ticker.
ERAS lobbying filings, year to date.
Registered lobbying filings matched to Erasca Inc.